Anti-inflammatory effects of PGE2 in the lung: Role of the EP4 receptor subtype

Thorax

Volumn 70, Issue 8, 2015, Pages 740-747

  Birrell, Mark A ^a,b   Maher, Sarah A ^a   Dekkak, Bilel ^a   Jones, Victoria ^a   Wong, Sissie ^a   Brook, Peter ^a   Belvisi, Maria G ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CIGARETTE SMOKE; CYCLIC AMP DEPENDENT PROTEIN KINASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OVALBUMIN; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; PROSTAGLANDIN E RECEPTOR; PTGER4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; POLLUTANT; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; FEMALE; LUNG; METABOLISM; PATHOLOGY;

ANIMALS; ASTHMA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84940465627     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206592     Document Type: Article

References (35)

1. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. World Health Organization, 2007:12-36.
2. Piper P, Vane J. The release of prostaglandins from lung and other tissues. Ann N Y Acad Sci 1971; 180:363-85.
3. Martin JG, Suzuki M, Maghni K., et al. The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat. J Immunol 2002; 169:3963-9.
4. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1999; 159:31-6.
5. Pavord ID, Wong CS, Williams J, et al. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 1993; 148:87-90.
6. Costello JF, Dunlop LS, Gardiner PJ. Characteristics of prostaglandin induced cough in man. Br J Clin Pharmacol 1985; 20:355-9.
7. Woodward D, Jones R, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011; 63:471-538.
8. Buckley J, Birrell MA, Maher S.A., et al. EP4 receptor as a new target for bronchodilator therapy. Thorax 2011; 66:1029-35.
9. Maher SA, Birrell MA, Belvisi MG. Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med 2009; 180:923-8.
10. Segi E, Sugimoto Y, Yamasaki A., et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998; 246:7-12.
11. Kilkenny C, Browne W, Cuthill I. The ARRIVE guidelines. ReqartoCom 2010; 8:1-2.
12. Eltom S, Stevenson CS, Rastrick J, et al. P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One 2011; 6:e24097-e24097.
13. Rastrick JMD, Stevenson CS, Eltom S, et al. Correction: cigarette smoke induced airway inflammation is independent of NF-κB signalling. PLoS ONE 2013; 8: e54128.
14. Birrell MA, De Alba J, Catley MC, et al. Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J Immunol 2008; 181:4265-71.
15. Birrell MA, Maher SA, Buckley J, et al. Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br J Pharmacol 2013; 168:129-38.
16. Roscioni SS, Dekkers BGJ, Prins AG, et al. cAMP inhibits modulation of airway smooth muscle phenotype via the exchange protein activated by cAMP (EPAC) and protein kinase A. Br J Pharmacol 2011; 162:193-209.
17. Gjertsen BT, Mellgren G, Otten A., et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1β action. J Biol Chem 1995; 270:20599-607.
18. Birrell MA, Wong S, Catley M.C., et al. Impact of tobacco-smoke on key signaling pathways in the innate immune response in lung macrophages. J Cell Physiol 2008; 214:27-37.
19. Nataraj C, Thomas DW, Tilley S.L., et al. Receptors for prostaglandin E (2) that regulate cellular immune responses in the mouse. J Clin Invest 2001; 108:1229-35.
20. Ratcliffe MJ, Walding A, Shelton P.A., et al. Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages. Eur Respir J 2007; 29:986-94.
21. Konya V, Philipose S, Bálint Z, et al. Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors. Eur J Immunol 2011; 41:2379-89.
22. Konya V, Üllen A, Kampitsch N, et al. Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. J Allergy Clin Immunol 2013; 131:532-40.
23. Shi M, Shi G, Tang J., et al. Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice. J Allergy Clin Immunol 2014; 134:1163-74.
24. Kunikata T, Yamane H, Segi E., et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 2005; 6:524-31.
25. Weller CL, Collington SJ, Hartnell A, et al. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci USA 2007; 104:11712-17.
26. Sturm EM, Schratl P, Schuligoi R., et al. Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J Immunol 2008; 181:7273-83.
27. Zasłona Z, Okunishi K, Bourdonnay E., et al. Prostaglandin E2 suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells. J Allergy Clin Immunol 2014; 133:379-87.
28. Pavlovic S, Du B, Sakamoto K., et al. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem 2006; 281:3321-8.
29. Katsuyama M, Ikegami R, Karahashi H., et al. Characterization of the LPS-stimulated expression of EP2 and EP4 prostaglandin E receptors in mouse macrophage-like cell line, J774.1. Biochem Biophys Res Commun 1998; 251:727-31.
30. Kubo S, Takahashi HK, Takei M, et al. E-prostanoid (EP) 2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization. J Pharmacol Exp Ther 2004; 309:1213-20.
31. Zhong WW, Burke PA, Drotar M.E., et al. Effects of prostaglandin E2, cholera toxin and 8-bromocyclic AMP on lipopolysaccharide-induced gene expression of cytokines in human macrophages. Immunology 1995; 84:446-52.
32. Minami M, Shimizu K, Okamoto Y., et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J Biol Chem 2008; 283:9692-703.
33. Bradbury D, Clarke D, Seedhouse C., et al. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005; 280:29993-30000.
34. Wall EA, Zavzavadjian JR, Chang M.S., et al. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signal 2009; 2:ra28.
35. Luschnig-Schratl P, Sturm EM, Konya V, et al. EP4 receptor stimulation down-regulates human eosinophil function. Cell Mol Life Sci 2011; 68:3573-87.